Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Clinical trial NCT05422911 · RECRUITING

Trial details

NCT number: NCT05422911
Sponsor: Sun Pharmaceutical Industries Limited
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Cancer Neoplasm, Prostate Castrate-sensitive Castrate-sensitive Prostate Cancer

Start date: 2022-08-31
Primary completion: 2027-12-31
Enrollment: 192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.